SAFEs vs Convertible Notes: Investor Red Flags

If you invest in early-stage startups, you’ll see the same two instruments over and over again: SAFEs and convertible notes. They can both be legitimate ways to fund a company before a priced equity round. They can also both hide terms that quietly shift risk onto you, the investor.

This article is a practical red-flag guide, written from the investor’s perspective. It’s not legal or tax advice, and it’s not a recommendation to buy or sell any security. It’s meant to help you ask better questions, spot common issues earlier, and make cleaner decisions.

Before we get into red flags, a quick reminder: early-stage private investing is speculative and illiquid. You can lose your entire investment, and you may not have the ability to sell or transfer your position for years, if ever. Terms matter because outcomes are uncertain.

Quick definitions (plain English)

What is a SAFE?

A SAFE (Simple Agreement for Future Equity) is a contract where you invest money now in exchange for the right to receive equity later, usually when the company raises a future “priced” round. Most SAFEs do not accrue interest and do not have a maturity date.

What is a convertible note?

A convertible note is debt today that typically converts into equity later. Notes usually accrue interest and have a maturity date. If conversion doesn’t happen by maturity, the note may become due and payable, or it may renegotiate. For more insights on this type of financing, check out this comprehensive guide on venture debt and the fundamentals of convertible notes.

In practice, both instruments are “bridge” financing. The difference is how much leverage and protection you actually have if things don’t go as planned.

The biggest investor misconception

Many investors assume SAFEs are “founder-friendly” and notes are “investor-friendly.” That can be true, but it’s not reliable. A SAFE can be drafted to heavily protect an investor, and a note can be drafted to leave an investor with few practical remedies.

So instead of arguing SAFE versus note in the abstract, focus on this:

What happens if the company does not raise the next round on the expected timeline?

That question reveals most of the real risk.

Red flags for SAFEs

1) No clear definition of the conversion trigger

A SAFE typically converts when there’s an “Equity Financing” that meets a minimum threshold. If the threshold is too high, or the definition is too narrow, your conversion might never trigger.

Red flag language to look for:

• A very high minimum financing amount to qualify as an “Equity Financing”

• Exclusions that carve out common venture structures

• Vague references to “acceptable” financing at the company’s discretion

Questions to ask:

• What events cause conversion besides a priced round (change of control, IPO, dissolution)?

• What is the minimum financing amount required, and why that number?

2) The SAFE is “post-money” and the cap is misunderstood

Post-money SAFEs can be fine, but they are frequently misunderstood. With a post-money SAFE, your ownership is typically easier to model relative to other SAFEs in the same round, but you can still be diluted by later SAFEs, option pool increases, and future rounds.

Common investor pitfall: assuming the cap equals the valuation you’re “buying in at,” without modeling future dilution.

Questions to ask:

• Is this SAFE pre-money or post-money?

• What other SAFEs are outstanding, and on what terms?

• Is the company planning to expand the option pool before the next priced round?

3) “MFN” is missing (or is drafted narrowly)

MFN (Most Favored Nation) provisions can protect early SAFE investors if the company later issues SAFEs with more favorable terms. If MFN is absent, the company can raise again tomorrow with a lower cap, a better discount, or extra investor rights, and you don’t benefit.

That said, MFN is not a cure-all. Some MFNs only apply to specific economic terms and exclude side letters and information rights.

Questions to ask:

• Is there an MFN clause?

• What terms does it actually cover (cap, discount, pro rata, information rights)?

• Does it exclude “side letters” or “other arrangements”?

4) No discount and a high cap (or no cap at all)

A SAFE can have:

• a valuation cap

• a discount

• both

• or neither

A SAFE with no cap and no discount is a major “read the room” moment. Sometimes it appears in very hot deals. Other times it’s a sign the round is being filled with unsophisticated capital.

A high cap without a discount can also function like “you take early risk without early reward.”

Questions to ask:

• Why is the cap set at this level relative to traction?

• If there is no discount, what investor-friendly terms offset that?

5) Pro rata rights are absent (or impossible to use)

Pro rata rights allow you to invest more in the next round to maintain your ownership. Many SAFEs offer no pro rata rights, or they require minimum checks that don’t fit smaller investors.

Even when pro rata exists, it can be practically unusable if allocations are discretionary or if the company historically favors large funds.

Questions to ask:

• Are pro rata rights included in the SAFE or via side letter?

• Are they guaranteed or “best efforts”?

• Is there a minimum investment amount to exercise them?

6) The SAFE stacks on top of a crowded cap table

One of the most important diligence items is how much is already ahead of you in the conversion line. If a company has multiple SAFE rounds plus notes plus a growing option pool, a new SAFE can end up converting into a smaller slice than you expect.

This isn’t automatically bad, but it’s a red flag if the company can’t clearly explain the cap table and fully diluted picture.

Questions to ask:

• What is the total outstanding in SAFEs and notes (principal + accrued interest)?

• What is the fully diluted cap table today, including the option pool and promised equity?

7) Control terms hidden in side letters you never see

A common issue in smaller rounds is inconsistent investor documentation. Some investors receive side letters with information rights, pro rata, or other benefits. Others do not.

Red flag: you’re told “everyone is on the same terms” but documentation suggests otherwise.

Questions to ask:

• Are any investors receiving side letters?

• If yes, can the company summarize what rights are being granted and whether they’re available to you?

8) Governance and information rights are minimal

Many SAFEs provide little ongoing visibility. If you do not receive updates, you may learn about problems only when it’s too late.

This becomes a bigger red flag when the company has limited operating history, limited financial reporting, or a complex regulatory posture.

Questions to ask:

• Will the company provide quarterly updates and basic financials?

• Is there an investor relations cadence?

Red flags for Convertible Notes

1) Maturity date with no realistic plan to convert or repay

A maturity date can be investor-protective in theory. In practice, if the company can’t raise, it often can’t repay either. The “protection” becomes a negotiation point, not cash in your pocket.

Red flag: a short maturity date (e.g., 12 months) paired with weak traction and no clear financing roadmap.

Questions to ask:

• What is the plan to reach the next priced round before maturity?

• What happens at maturity if there is no qualified financing?

• Have prior notes been extended repeatedly?

• Are there any tax consequences associated with the convertible note that I should be aware of?

2) High interest rate that looks good but doesn’t help you much

Interest accrual can feel like upside, but interest usually converts into equity at the same terms as principal. If the company stalls, interest doesn’t matter because the real risk is total loss or an unfavorable down-round conversion.

Red flag: interest rate is presented as a “return,” especially to newer investors, without discussing default and liquidity realities.

Questions to ask:

• Does interest accrue and convert, or must it be paid in cash?

• Is there any scenario where interest is actually paid?

3) Ambiguous or investor-unfriendly conversion mechanics

Notes vary widely on conversion terms. Some convert at the next round automatically. Some convert only if the round meets a threshold. Some allow the majority of noteholders to force terms that may not benefit smaller holders.

Questions to ask:

• Is conversion automatic or optional?

• Is there a minimum financing amount required to trigger conversion?

• Can a majority of noteholders amend terms without your consent?

4) Security interests and guarantees that are meaningless in reality

Some notes mention being “secured” or having certain covenants. That can be meaningful if there are real assets and the security interest is properly documented and perfected. Many early-stage startups have few hard assets, and enforcement can be expensive and uncertain.

Red flag: a “secured note” is used as a marketing line without clear collateral, filing details, or a realistic enforcement path.

Questions to ask:

• What exactly is the collateral?

• Is there a UCC filing (or equivalent) planned or already done?

• Who else is senior to you?

5) Repayment rights that create perverse incentives

A note that becomes payable at maturity can push a company into a corner. Sometimes that’s good pressure. Sometimes it causes the company to accept a low-quality round just to trigger conversion, or to negotiate a punitive extension that harms smaller investors.

Questions to ask:

• Is there a built-in extension option, and on what terms?

• Are there default penalties, and who benefits from them?

6) Cap table complexity from multiple note rounds

If a company has notes across multiple rounds with different caps, discounts, and maturity dates, you can end up with complicated conversion waterfalls. While cap tables themselves are not inherently bad, it becomes a red flag when management can’t clearly explain outcomes under different scenarios.

Questions to ask:

• Can you see a modeled conversion table under a few valuation outcomes?

• How do older notes interact with new notes?

Red flags for Process and Transparency

1) “It’s standard” used as a conversation ender

There is no single universal standard. There are market norms, and they shift by stage, sector, and demand. If someone uses “standard” to shut down basic questions, that’s a red flag about transparency, not necessarily about terms.

What you want instead: a calm explanation of why the terms are set that way.

2) Missing or inconsistent disclosure about existing obligations

You should understand what else sits on the cap table: SAFEs, notes, venture debt, revenue-based financing, major vendor obligations, and any unusual contractual commitments.

Red flag: the company won’t provide a clean summary of outstanding securities and material liabilities.

3) Unrealistic valuation signaling

A valuation cap that is dramatically out of line with traction can be a sign that the round is being priced for marketing, not fundamentals. That doesn’t mean the company can’t succeed, but it increases the chance of a down round, painful dilution, or a stalled financing process.

Investor mindset: caps are not just a number. They are a story about what the next round must look like for the instrument to work smoothly.

4) No clear path to a priced round

A SAFE or note is a bridge. A bridge should lead somewhere. If the company is raising “because runway” without clear milestones and a timeline, you may be funding drift.

Questions to ask:

• What milestones will unlock the next priced round (revenue, retention, regulatory approval, product launch)?

• What is the financing plan if milestones take longer?

5) “We’ll fix it in the priced round”

Some issues can be fixed later. Many cannot, especially if the company’s leverage changes. If the docs are unclear today, you should assume clarity will not magically improve later when the company is stressed.

6) Overreliance on hype-driven outcomes

Be wary of narratives that rely on a single event: “We’ll definitely raise a Series A,” “We’re about to sign a huge partnership,” “We’ll get acquired quickly.” Outcomes happen, but certainty language is a red flag in private markets.

Neither instrument is inherently safer. The “safety” comes from:

• the company’s fundamentals and governance

• your price and dilution risk (cap, discount, stack ahead of you)

• your downside rights (maturity, repayment, information)

• how the docs handle non-ideal scenarios

That said, here’s a practical rule many experienced investors follow:

• If you trust the team, the round is clean, and the pricing is fair, a SAFE can be efficient.

• If timelines are uncertain and you want defined leverage points, a note can create negotiation structure, but only if the terms are realistic and enforceable.

Both can still go to zero.

Use this as a quick screen before you wire funds.

Company and round basics

• How much is being raised in this round, and what is the runway impact?

• How much has already been raised on SAFEs/notes, and on what terms?

• What is the fully diluted cap table today (including option pool)?

SAFE-specific

• Is it pre-money or post-money?

• What is the valuation cap and/or discount?

• Is there MFN?

• What triggers conversion besides a priced round?

• Are pro rata rights included? If yes, are they practical?

Note-specific

• What is the interest rate and how is it treated at conversion?

• What is the maturity date?

• What happens at maturity if no qualified financing occurs?

• Is conversion automatic or optional?

• Are amendments controlled by a majority of noteholders?

Process and transparency

• Do you receive periodic investor updates and basic financial reporting?

• Are side letters being used, and are rights consistent across investors?

• Is counsel involved, and are documents internally consistent?

If you can’t get clear answers to these, pause. It’s not being “difficult.” It’s doing the job.

One underappreciated risk in private investing is administrative drift: scattered PDFs, missing countersigns, forgotten side letters, and no single place to track positions across public and private holdings.

If you’re building a portfolio across both markets, a platform like Braintrust can be helpful for consolidating how you research, access, and manage investments in one place. In particular, having an organized workflow for deal documents, portfolio views, and ongoing monitoring can reduce avoidable mistakes. You can explore Braintrust at: https://www.braintrustinvest.com

(As always, availability of private investments and features can depend on eligibility, account type, and offering terms. Nothing here is an offer to sell or a solicitation to buy securities.)

SAFEs and convertible notes are not “gotchas” by default. They’re tools. The red flags show up when:

• conversion depends on unrealistic assumptions

• the cap table is crowded and poorly explained

• rights are unevenly distributed via side letters

• maturity and repayment terms sound strong but aren’t practical

• the company avoids direct answers

If you want a single investor habit that pays off: ask what happens in the boring, unglamorous scenarios. No priced round for 24 months. A small round that doesn’t meet the threshold. A down round. An acquisition at a modest price. A shutdown.

When the docs address those scenarios clearly, you’re usually looking at a more professional deal process. When they don’t, that’s when investors get surprised.

Disclosures: This article is for informational and educational purposes only and does not constitute investment advice, legal advice, tax advice, or a recommendation regarding any security, strategy, or account. Private investments are speculative, involve significant risk, are illiquid, and may result in a total loss of capital. Terms discussed are generalized and may vary widely by offering. Investors should review offering documents carefully and consult their own legal, tax, and financial advisors before investing.